Search: WFRF:(MacFarlane M) >
Drug retention, ina...
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration
- Article/chapterEnglish2020
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/301665
-
https://gup.ub.gu.se/publication/301665URI
-
https://doi.org/10.1136/rmdopen-2020-001280DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:232950963URI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries. METHODS: Real-life data from 13 European registries participating in the European Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier with log-rank test, Cox regression, χ² and logistic regression analyses were performed to assess 6-month and 12-month secukinumab retention, inactive disease/low-disease-activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <2/<4, Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3/<2.1) and response rates (BASDAI50, Assessment of Spondyloarthritis International Society (ASAS) 20/40, ASDAS clinically important improvement (ASDAS-CII) and ASDAS major improvement (ASDAS-MI)). RESULTS: We included 1860 patients initiating secukinumab as part of routine care. Overall 6-month/12-month secukinumab retention rates were 82%/72%, with significant (p<0.001) differences between the registries (6-month: 70-93%, 12-month: 53-86%) and across number of previous b/tsDMARDs (b/tsDMARD-naïve: 90%/73%, 1 prior b/tsDMARD: 83%/73%, ≥2 prior b/tsDMARDs: 78%/66%). Overall 6-month/12-month BASDAI<4 were observed in 51%/51%, ASDAS<1.3 in 9%/11%, BASDAI50 in 53%/47%, ASAS40 in 28%/22%, ASDAS-CII in 49%/46% and ASDAS-MI in 25%/26% of the patients. All rates differed significantly across number of previous b/tsDMARDs, were numerically higher for b/tsDMARD-naïve patients and varied significantly across registries. Overall, time since diagnosis was not associated with secukinumab effectiveness. CONCLUSIONS: In this study of 1860 patients from 13 European countries, we present the first comprehensive real-life data on effectiveness of secukinumab in patients with axSpA. Overall, secukinumab retention rates after 6 and 12months of treatment were high. Secukinumab effectiveness was consistently better for bionaïve patients, independent of time since diagnosis and differed across the European countries. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Lindström, UlfGothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research(Swepub:gu)xlulfn
(author)
-
Codreanu, C.
(author)
-
Ciurea, A.
(author)
-
Zavada, J.
(author)
-
Loft, A. G.
(author)
-
Pombo-Suarez, M.
(author)
-
Onen, F.
(author)
-
Kvien, T. K.
(author)
-
Rotar, Z.
(author)
-
Santos, M. J.
(author)
-
Iannone, F.
(author)
-
Hokkanen, A. M.
(author)
-
Gudbjornsson, B.
(author)
-
Askling, J.Karolinska Institutet
(author)
-
Ionescu, R.
(author)
-
Nissen, M. J.
(author)
-
Pavelka, K.
(author)
-
Sanchez-Piedra, C.
(author)
-
Akar, S.
(author)
-
Sexton, J.
(author)
-
Tomsic, M.
(author)
-
Santos, H.
(author)
-
Sebastiani, M.
(author)
-
Österlund, J.
(author)
-
Geirsson, A. J.
(author)
-
Macfarlane, G.
(author)
-
van der Horst-Bruinsma, I.
(author)
-
Georgiadis, S.
(author)
-
Brahe, C. H.
(author)
-
Ørnbjerg, L. M.
(author)
-
Hetland, M. L.
(author)
-
Østergaard, M.
(author)
-
Göteborgs universitetInstitutionen för medicin, avdelningen för reumatologi och inflammationsforskning
(creator_code:org_t)
Related titles
-
In:RMD open: BMJ6:32056-5933
Internet link
Find in a library
-
RMD open
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Michelsen, B.
-
Lindström, Ulf
-
Codreanu, C.
-
Ciurea, A.
-
Zavada, J.
-
Loft, A. G.
-
show more...
-
Pombo-Suarez, M.
-
Onen, F.
-
Kvien, T. K.
-
Rotar, Z.
-
Santos, M. J.
-
Iannone, F.
-
Hokkanen, A. M.
-
Gudbjornsson, B.
-
Askling, J.
-
Ionescu, R.
-
Nissen, M. J.
-
Pavelka, K.
-
Sanchez-Piedra, ...
-
Akar, S.
-
Sexton, J.
-
Tomsic, M.
-
Santos, H.
-
Sebastiani, M.
-
Österlund, J.
-
Geirsson, A. J.
-
Macfarlane, G.
-
van der Horst-Br ...
-
Georgiadis, S.
-
Brahe, C. H.
-
Ørnbjerg, L. M.
-
Hetland, M. L.
-
Østergaard, M.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Rheumatology and ...
- Articles in the publication
-
RMD open
- By the university
-
University of Gothenburg
-
Karolinska Institutet